Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients

NCT00652340 is registered in ClinicalTrials.gov with Tragara Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00652340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00652340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients
Lead sponsor
Tragara Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
March 31, 2012
Enrollment
120 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent non small cell lung cancer